| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline.
Nugevia's debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter's proprietary JOTROL™ micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space.
A New Standard in Evidence-Based Supplementation
Nugevia's first three formulations—targeting mitochondrial support, mental clarity, and "beauty from within"—will be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL™, Jupiter's enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL™ is also the foundation of Jupiter's ongoing therapeutic programs in Parkinson's and Alzheimer's disease.
Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization.
Strategic Synergy with Core Pipeline
The Nugevia launch adds a new dimension to Jupiter's value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach $8 trillion by 2030.
The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model.
Posted In: JUNS
